BG105608A - N-[4-(3-chloro-4-fluoro-phenylamino(-7-(3-morpholin-4-yl- propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases - Google Patents

N-[4-(3-chloro-4-fluoro-phenylamino(-7-(3-morpholin-4-yl- propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases

Info

Publication number
BG105608A
BG105608A BG105608A BG10560801A BG105608A BG 105608 A BG105608 A BG 105608A BG 105608 A BG105608 A BG 105608A BG 10560801 A BG10560801 A BG 10560801A BG 105608 A BG105608 A BG 105608A
Authority
BG
Bulgaria
Prior art keywords
morpholin
propoxy
acrylamide
fluoro
chloro
Prior art date
Application number
BG105608A
Other languages
Bulgarian (bg)
Inventor
Alexander BRIDGES
Denise Driscoll
Wayne KLOHS
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG105608A publication Critical patent/BG105608A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides the compound N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)- quinazolin-6-yl]-acrylamide that is an irreversible inhibitor of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis and psoriasis using the compound N-[4-(3-chloro-4-fluoro-pheylamino)-7-(3-morpholin-4-yl-propoxy)- quinazolin-6-yl]-acrylamide, and a pharmaceutical composition that contains the compound N-[4-(3-chloro-4-fluoro-phenylamino-7-(3-morpholin-4-yl-propoxy-qu inazolin-6-yl]-acrylamide. 15 claims.
BG105608A 1998-11-19 2001-06-15 N-[4-(3-chloro-4-fluoro-phenylamino(-7-(3-morpholin-4-yl- propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases BG105608A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10906598P 1998-11-19 1998-11-19
PCT/US1999/022116 WO2000031048A1 (en) 1998-11-19 1999-09-23 N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases

Publications (1)

Publication Number Publication Date
BG105608A true BG105608A (en) 2002-01-31

Family

ID=22325607

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105608A BG105608A (en) 1998-11-19 2001-06-15 N-[4-(3-chloro-4-fluoro-phenylamino(-7-(3-morpholin-4-yl- propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases

Country Status (30)

Country Link
US (1) US6344455B1 (en)
EP (1) EP1131304B1 (en)
JP (1) JP3687900B2 (en)
KR (1) KR20010080491A (en)
CN (1) CN1160338C (en)
AR (1) AR023706A1 (en)
AT (1) ATE229008T1 (en)
AU (1) AU763626B2 (en)
BG (1) BG105608A (en)
BR (1) BR9915487A (en)
CA (1) CA2349721A1 (en)
CO (1) CO5150185A1 (en)
CZ (1) CZ20011759A3 (en)
DE (1) DE69904358T2 (en)
DK (1) DK1131304T3 (en)
EA (1) EA003786B1 (en)
EE (1) EE200100271A (en)
ES (1) ES2188254T3 (en)
GE (1) GEP20032997B (en)
HU (1) HUP0104211A3 (en)
IL (1) IL143089A0 (en)
NO (1) NO319357B1 (en)
NZ (2) NZ527718A (en)
PE (1) PE20001242A1 (en)
PL (1) PL347717A1 (en)
PT (1) PT1131304E (en)
SK (1) SK283688B6 (en)
UY (1) UY25809A1 (en)
WO (1) WO2000031048A1 (en)
ZA (1) ZA200103535B (en)

Families Citing this family (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
UA73993C2 (en) * 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
DE10031971A1 (en) * 2000-06-30 2002-01-10 Goedecke Ag Polymorphic forms / hydrates of N- [4- (3-chloro-4-fluoro-phenylamino) -7- (3-morpholin-4-yl-propoxy) -quinazolin-6-yl] -acrylamide dihydrochloride, process for their preparation and the use thereof for the manufacture of medicaments with irreversible tyrosine kinase inhibitory activity
EP1170011A1 (en) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
WO2002011677A2 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10042064A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Chinazolines, medicaments containing these compounds, their use and processes for their preparation
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
NZ516873A (en) * 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
WO2003062421A1 (en) 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
DE10221018A1 (en) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
EP1510221A4 (en) * 2002-06-03 2009-04-29 Mitsubishi Tanabe Pharma Corp PREVENTIVE AND / OR THERAPEUTIC MEANS FOR SUBJECTS HAVING THE EXPRESSION OR ACTIVATION OF HER2 AND / OR EGFR
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
CA2527680A1 (en) 2003-05-30 2005-06-02 Astrazeneca Uk Limited Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor
WO2005001053A2 (en) 2003-06-09 2005-01-06 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
DK1660090T3 (en) 2003-08-14 2012-12-17 Array Biopharma Inc QUINAZOLINE ANALOGS AS RECEPTOR-TYROSINKINASE INHIBITORS
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0321620D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
ATE395346T1 (en) * 2003-09-16 2008-05-15 Astrazeneca Ab QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
KR20080095915A (en) * 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-phenylamino-quinazolin-6-yl-amide
BRPI0510717B8 (en) 2004-05-06 2021-05-25 Bioresponse Llc use of 3,3'-diindolylmethane (dim) or 2-(indol-3-ylmethyl)-3,3'-diindolylmethane (ltr)
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
ATE428421T1 (en) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd MEDICAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELING PROPERTIES
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
ATE497762T1 (en) 2004-12-30 2011-02-15 Bioresponse Llc USE OF DIINDOLYLMETHANE-RELATED INDOLES FOR THE TREATMENT AND PREVENTION OF DISEASES RELATED TO THE RESPIRATORY SYNCYTIAL VIRUS
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
JP4989476B2 (en) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for assaying the effects of angiogenesis inhibitors
JP2009505658A (en) 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー Biomarkers and methods for determining susceptibility to epidermal growth factor receptor modulators
KR100832594B1 (en) * 2005-11-08 2008-05-27 한미약품 주식회사 Quinazoline derivatives as an multiplex inhibitor and method for the preparation thereof
JP5688877B2 (en) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Quinazoline derivatives for the treatment of cancer diseases
ATE446294T1 (en) 2005-11-15 2009-11-15 Array Biopharma Inc N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
CN104706637A (en) 2006-05-18 2015-06-17 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
ES2372217T3 (en) 2006-09-12 2012-01-17 Genentech, Inc. PROCEDURES AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF LUNG CANCER USING THE GENE OF PDGFRA, KIT OR KDR AS A GENETIC MARKER.
AU2007299080B2 (en) 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
US8586621B2 (en) 2006-10-27 2013-11-19 Michael A. Zeligs Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009067543A2 (en) * 2007-11-19 2009-05-28 The Regents Of The University Of Colorado Treatment of histone deacetylase mediated disorders
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
EP2262522A1 (en) * 2008-03-07 2010-12-22 Pharma Mar, S.A. Improved antitumoral treatments
CN101544609A (en) 2008-03-25 2009-09-30 上海艾力斯医药科技有限公司 Crystallization form of 4-anilinoquinazoline derivatives
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
PT2451445T (en) 2009-07-06 2019-07-10 Boehringer Ingelheim Int Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
EP2494070A2 (en) 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
US20110110942A1 (en) 2009-11-12 2011-05-12 Genentech, Inc. Method of promoting dendritic spine density
JP2013516422A (en) 2009-12-30 2013-05-13 アビラ セラピューティクス， インコーポレイテッド Protein ligand-directed covalent modification
RU2012132278A (en) 2010-01-12 2014-02-20 Ф. Хоффманн-Ля Рош Аг TRICYCLIC HETEROCYCLIC COMPOUNDS CONTAINING THEIR COMPOSITIONS AND WAYS OF THEIR APPLICATION
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
WO2011130654A1 (en) 2010-04-16 2011-10-20 Genentech, Inc. Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
CN102958523B (en) 2010-06-25 2014-11-19 卫材R&D管理有限公司 Use of combined antineoplastic agents with kinase inhibitory effects
MX2013002084A (en) 2010-08-31 2013-05-09 Genentech Inc BIOMARKERS AND TREATMENT METHODS.
TW201217387A (en) 2010-09-15 2012-05-01 Hoffmann La Roche Azabenzothiazole compounds, compositions and methods of use
BR112013011520A2 (en) 2010-11-19 2019-09-24 Hoffmann La Roche pyrazolo pyridines and pyrazolo pyridines and their use as tyk2 inhibitors
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
CN103402519B (en) 2011-04-18 2015-11-25 卫材R&D管理有限公司 Therapeutic agent for tumor
GB201106870D0 (en) 2011-04-26 2011-06-01 Univ Belfast Marker
JP6038128B2 (en) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
KR20140047160A (en) 2011-08-12 2014-04-21 에프. 호프만-라 로슈 아게 Indazole compounds, compositions and methods of use
MX2014001766A (en) 2011-08-17 2014-05-01 Genentech Inc Neuregulin antibodies and uses thereof.
CN103827115A (en) 2011-09-20 2014-05-28 弗·哈夫曼-拉罗切有限公司 Imidazopyridine compounds, compositions and methods of use
EP2766497A1 (en) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
BR112014012979A2 (en) 2011-11-30 2020-10-20 Genentech, Inc. erbb3 mutations in cancer
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
KR20150098605A (en) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous form of quinoline derivative, and method for producing same
JP2016509045A (en) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト How to treat cancer and prevent drug resistance
MX2015011428A (en) 2013-03-06 2016-02-03 Genentech Inc Methods of treating and preventing cancer drug resistance.
KR20150130491A (en) 2013-03-13 2015-11-23 제넨테크, 인크. Pyrazolo compounds and uses thereof
JP2016516046A (en) 2013-03-14 2016-06-02 ジェネンテック， インコーポレイテッド Methods for treating cancer and methods for preventing cancer drug resistance
MX2015010854A (en) 2013-03-14 2016-07-20 Genentech Inc Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use.
CA2905123A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103242244B (en) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 Canertinib preparation method
EP3041474B1 (en) 2013-09-05 2020-03-18 Genentech, Inc. Antiproliferative compounds
CN104513229A (en) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 Quinazoline derivatives and preparation method thereof
TW201605857A (en) 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Therapeutic inhibitors of CDK8 and uses thereof
BR112016008477A2 (en) 2013-10-18 2017-10-03 Genentech Inc BODIES, NUCLEIC ACID, HOST CELL, METHOD OF PRODUCING AN ANTIBODY, IMMUNOCONJUGATE, PHARMACEUTICAL FORMULATION AND USES OF THE ANTIBODY
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP2017507900A (en) 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Method for treating HER2-positive cancer using PD-1 axis binding antagonist and anti-HER2 antibody
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
RU2016141385A (en) 2014-03-24 2018-04-28 Дженентек, Инк. CANCER TREATMENT WITH C-MET ANTAGONISTS AND THEIR CORRELATION WITH HGF EXPRESSION
SG11201607969XA (en) 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
KR20160146747A (en) 2014-03-31 2016-12-21 제넨테크, 인크. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
PT3524595T (en) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd HIGHLY PURE QUINOLINE DERIVATIVE AND METHOD FOR PRODUCTION THEREOF
CN107074823B (en) 2014-09-05 2021-05-04 基因泰克公司 Therapeutic compounds and their uses
EP3193866A1 (en) 2014-09-19 2017-07-26 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
CN107912040B (en) 2014-10-10 2021-04-06 基因泰克公司 Pyrrolidinamide compounds as histone demethylase inhibitors
US20170252335A1 (en) 2014-10-17 2017-09-07 Novartis Ag Combination of Ceritinib with an EGFR Inhibitor
CA2966523A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
WO2016073380A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
US20160152720A1 (en) 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
CN107108613B (en) 2014-11-10 2020-02-25 基因泰克公司 Bromo domain inhibitors and their uses
MA40943A (en) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
MA40940A (en) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3632915A1 (en) 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
KR20170094165A (en) 2014-12-23 2017-08-17 제넨테크, 인크. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
JP2018503373A (en) 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド Methods and compositions for cancer prognosis and treatment
EP3242872B1 (en) 2015-01-09 2019-07-03 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
WO2016112251A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
EP3242874B1 (en) 2015-01-09 2018-10-31 Genentech, Inc. Pyridazinone derivatives and their use in the treatment of cancer
EP3250571B1 (en) 2015-01-29 2022-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016123387A1 (en) 2015-01-30 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
LT3263106T (en) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. METHOD OF REDUCING BITTERNESS OF QUINOLINE DERIVATIVES
MA41598A (en) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES
KR102662228B1 (en) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 Combination of PD-1 antagonists and VEGFR/FGFR/RET tyrosine kinase inhibitors to treat cancer
WO2016150340A1 (en) 2015-03-20 2016-09-29 正大天晴药业集团股份有限公司 Salts of quinazoline derivative and method for preparing same
KR20180002653A (en) 2015-04-07 2018-01-08 제넨테크, 인크. Antigen binding complexes having an agonistic activity activity and methods of use
ES2835866T5 (en) 2015-05-12 2024-12-02 Hoffmann La Roche Therapeutic and diagnostic procedures for cancer
ES2789500T5 (en) 2015-05-29 2023-09-20 Hoffmann La Roche Therapeutic and diagnostic procedures for cancer
MX2017015937A (en) 2015-06-08 2018-12-11 Genentech Inc Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists.
JP2018521019A (en) 2015-06-08 2018-08-02 ジェネンテック， インコーポレイテッド Method of treating cancer using anti-OX40 antibody
MX373231B (en) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd ANTICANCER AGENT.
KR102689256B1 (en) 2015-06-17 2024-07-30 제넨테크, 인크. Methods for treating locally advanced or metastatic breast cancer using PD-1 axis binding antagonists and taxanes
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
ES2862727T3 (en) 2015-08-26 2021-10-07 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Fused tricyclic compounds as protein kinase inhibitors
PE20181046A1 (en) 2015-09-25 2018-07-03 Genentech Inc ANTI-TIGIT ANTIBODIES AND METHODS OF USE
MY196817A (en) 2015-12-16 2023-05-03 Genentech Inc Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
KR20180097615A (en) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Methods for the treatment of CEA-positive cancers using PD-1 axis-binding antagonists and anti-CEA / anti-CD3 bispecific antibodies
CN105732522A (en) * 2016-02-01 2016-07-06 刘平 Medicine composition for treating periodontitis
JP6821693B2 (en) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド Treatment and diagnosis for cancer
EP3865511A1 (en) 2016-04-14 2021-08-18 F. Hoffmann-La Roche AG Anti-rspo3 antibodies and methods of use
KR20190003958A (en) 2016-04-15 2019-01-10 제넨테크, 인크. Treatment and monitoring of cancer
KR20180134347A (en) 2016-04-15 2018-12-18 제넨테크, 인크. Diagnosis and Treatment of Cancer
MX2018012493A (en) 2016-04-15 2019-06-06 Genentech Inc METHODS TO CONTROL AND TREAT CANCER.
JP7014736B2 (en) 2016-05-24 2022-02-01 ジェネンテック， インコーポレイテッド Pyrazolopyridine derivatives for the treatment of cancer
EP3464270B1 (en) 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
US20200129519A1 (en) 2016-06-08 2020-04-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
CA3038712A1 (en) 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2018078143A1 (en) 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
TW201837467A (en) 2017-03-01 2018-10-16 美商建南德克公司 For the diagnosis and treatment of cancer
CN110505883A (en) 2017-04-13 2019-11-26 豪夫迈·罗氏有限公司 Interleukin-2 immunoconjugates, CD40 agonists, and optionally PD-1 axis binding antagonists for use in methods of treating cancer
RU2019134940A (en) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. TREATMENT OF HEPATOCELLULAR CARCINOMA
JP7760242B2 (en) 2017-07-21 2025-10-27 ジェネンテック， インコーポレイテッド Cancer treatment and diagnosis methods
MX2020000903A (en) 2017-08-11 2020-07-22 Genentech Inc ANTI-CD8 ANTIBODIES AND USES THEREOF.
KR102811888B1 (en) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 Diagnosis and treatment of cancer
US11369608B2 (en) 2017-10-27 2022-06-28 University Of Virginia Patent Foundation Compounds and methods for regulating, limiting, or inhibiting AVIL expression
TW201923089A (en) 2017-11-06 2019-06-16 美商建南德克公司 Diagnostic and therapeutic methods for cancer
AU2019207535B2 (en) 2018-01-15 2021-12-23 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
CN111836831A (en) 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 Administration for Anti-TIGIT Antagonist Antibody and Anti-PD-L1 Antagonist Antibody Therapy
JP2021524744A (en) 2018-05-21 2021-09-16 ナノストリング テクノロジーズ，インコーポレイティド Molecular gene signature and how to use it
MY205645A (en) 2018-06-23 2024-11-02 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
WO2020018789A1 (en) 2018-07-18 2020-01-23 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
EP3847154A1 (en) 2018-09-03 2021-07-14 F. Hoffmann-La Roche AG Carboxamide and sulfonamide derivatives useful as tead modulators
AU2019342099A1 (en) 2018-09-19 2021-04-08 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
KR102739487B1 (en) 2018-09-21 2024-12-10 제넨테크, 인크. Diagnostic methods for triple-negative breast cancer
US12404540B2 (en) 2018-10-17 2025-09-02 The University Of Queensland Epigenetic biomarker and uses therefor
EP3867646A1 (en) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for sarcomatoid kidney cancer
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
CN113396230A (en) 2019-02-08 2021-09-14 豪夫迈·罗氏有限公司 Methods of diagnosis and treatment of cancer
CN113677994B (en) 2019-02-27 2025-09-09 外延轴治疗股份有限公司 Methods and agents for assessing T cell function and predicting response to therapy
WO2020176748A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
CN114269376A (en) 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 Methods of treating cancer with anti-PD-L1 antibodies
CN112300279A (en) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 Methods and compositions directed to anti-CD 73 antibodies and variants
TWI873176B (en) 2019-09-04 2025-02-21 美商建南德克公司 Cd8 binding agents and uses thereof
JP2022548978A (en) 2019-09-27 2022-11-22 ジェネンテック， インコーポレイテッド Dosing for Treatment with Drugs Anti-TIGIT and Anti-PD-L1 Antagonist Antibodies
JP2023511472A (en) 2019-10-29 2023-03-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bifunctional compounds for the treatment of cancer
KR20220092580A (en) 2019-11-06 2022-07-01 제넨테크, 인크. Diagnosis and treatment methods for the treatment of blood cancer
TW202130618A (en) 2019-11-13 2021-08-16 美商建南德克公司 Therapeutic compounds and methods of use
CN110963972A (en) * 2019-11-21 2020-04-07 苏州明锐医药科技有限公司 Quinazoline derivative, preparation method and pharmaceutical application thereof
WO2021119505A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
CA3164995A1 (en) 2019-12-20 2021-06-24 Erasca, Inc. Tricyclic pyridones and pyrimidones
TW202142230A (en) 2020-01-27 2021-11-16 美商建南德克公司 Methods for treatment of cancer with an anti-tigit antagonist antibody
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
AU2021293038A1 (en) 2020-06-16 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating triple-negative breast cancer
KR20230024368A (en) 2020-06-18 2023-02-20 제넨테크, 인크. Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
JP2023536602A (en) 2020-08-03 2023-08-28 ジェネンテック， インコーポレイテッド Diagnostic and therapeutic methods for lymphoma
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
JP2023544450A (en) 2020-09-23 2023-10-23 エラスカ・インコーポレイテッド Tricyclic pyridones and pyrimidone
CN116406291A (en) 2020-10-05 2023-07-07 基因泰克公司 Administration of Therapy with Anti-FCRH5/Anti-CD3 Bispecific Antibody
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
AU2022221124A1 (en) 2021-02-12 2023-08-03 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
KR20240026948A (en) 2021-05-25 2024-02-29 에라스카, 아이엔씨. Sulfur-containing heteroaromatic tricyclic KRAS inhibitor
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
TW202321261A (en) 2021-08-10 2023-06-01 美商伊瑞斯卡公司 Selective kras inhibitors
US12110276B2 (en) 2021-11-24 2024-10-08 Genentech, Inc. Pyrazolo compounds and methods of use thereof
US12275745B2 (en) 2021-11-24 2025-04-15 Genentech, Inc. Therapeutic compounds and methods of use
CN114634453B (en) * 2022-03-15 2023-10-10 沈阳工业大学 Preparation methods of quinazoline derivatives and their applications
IL315770A (en) 2022-04-01 2024-11-01 Genentech Inc Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
JP2025517650A (en) 2022-05-11 2025-06-10 ジェネンテック， インコーポレイテッド Administration for Treatment with Anti-FcRH5/Anti-CD3 Bispecific Antibody
KR20250022049A (en) 2022-06-07 2025-02-14 제넨테크, 인크. Method for determining the efficacy of a treatment for lung cancer comprising an anti-PD-L1 antagonist and an anti-TIGIT antagonist antibody
AU2023305619A1 (en) 2022-07-13 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20250040020A (en) 2022-07-19 2025-03-21 제넨테크, 인크. Dosage regimen for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
AU2023322637A1 (en) 2022-08-11 2024-11-14 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
AU2023322638A1 (en) 2022-08-11 2024-11-28 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
JP2025526726A (en) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bicyclic Tetrahydroazepine Derivatives
JP2025538859A (en) 2022-10-21 2025-12-02 公益財団法人川崎市産業振興財団 Non-adsorbing or super stealth vesicles
KR20250093336A (en) 2022-10-25 2025-06-24 제넨테크, 인크. Treatment and Diagnosis Methods for Multiple Myeloma
EP4665735A1 (en) 2023-02-17 2025-12-24 Erasca, Inc. Kras inhibitors
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20260021689A (en) 2023-06-08 2026-02-13 제넨테크, 인크. Macrophage Signatures for Lymphoma Diagnosis and Treatment
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
TW202515614A (en) 2023-08-25 2025-04-16 美商建南德克公司 Methods and compositions for treating non-small cell lung cancer
WO2026030476A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Precision medicine for optimal dosage of combined therapies systems and methods of use thereof
WO2026030464A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001595B1 (en) * 1996-04-12 2001-06-25 Варнер-Ламберт Компани Irreversible inhibitors of tyrosine kinases.

Also Published As

Publication number Publication date
AU763626B2 (en) 2003-07-31
AR023706A1 (en) 2002-09-04
EP1131304A1 (en) 2001-09-12
NZ512189A (en) 2003-10-31
NO20012465D0 (en) 2001-05-18
UY25809A1 (en) 2001-03-16
JP2002530386A (en) 2002-09-17
US6344455B1 (en) 2002-02-05
DK1131304T3 (en) 2003-03-24
IL143089A0 (en) 2002-04-21
PT1131304E (en) 2003-04-30
WO2000031048A1 (en) 2000-06-02
ZA200103535B (en) 2002-08-02
NO20012465L (en) 2001-07-13
CO5150185A1 (en) 2002-04-29
EA003786B1 (en) 2003-10-30
NZ527718A (en) 2004-11-26
CA2349721A1 (en) 2000-06-02
EE200100271A (en) 2002-10-15
CZ20011759A3 (en) 2002-01-16
PE20001242A1 (en) 2000-11-08
PL347717A1 (en) 2002-04-22
JP3687900B2 (en) 2005-08-24
HK1041695A1 (en) 2002-07-19
SK6572001A3 (en) 2002-02-05
ES2188254T3 (en) 2003-06-16
GEP20032997B (en) 2003-06-25
ATE229008T1 (en) 2002-12-15
HUP0104211A3 (en) 2003-01-28
HUP0104211A2 (en) 2002-05-29
SK283688B6 (en) 2003-12-02
CN1160338C (en) 2004-08-04
DE69904358T2 (en) 2003-04-17
NO319357B1 (en) 2005-07-18
BR9915487A (en) 2001-07-31
EP1131304B1 (en) 2002-12-04
AU6261299A (en) 2000-06-13
EA200100546A1 (en) 2001-10-22
KR20010080491A (en) 2001-08-22
CN1330642A (en) 2002-01-09
DE69904358D1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
BG105608A (en) N-[4-(3-chloro-4-fluoro-phenylamino(-7-(3-morpholin-4-yl- propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
CA2249446A1 (en) Irreversible inhibitors of tyrosine kinases
TW200420544A (en) Preparation of substituted quinazolines
PL348605A1 (en) Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
IL134013A (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
EP0981607A4 (en) Modiified arginine deiminase
NO20005864L (en) Quinazolines for the treatment of brain tumor
ATE242238T1 (en) QUINOLINE AND QUINAZOLINE COMPOUNDS OF THERAPEUTIC UTILITY, PARTICULARLY FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA
ZA986729B (en) Irreversible inhibitors of tyrosine kinases
LT2001023A (en) AN aP2 INHIBITOR AND COMBINATION FOR TREATING ATHEROSCLEROSIS
NO308037B1 (en) 16-substituted-4-aza-androstan 5 <alpha> reductase isoenzyme 1 inhibitors and pharmaceutical preparation
UA66793C2 (en) Leptin as inhibitor of tumor growth
ECSP993224A (en) N - [- 4- (3-CHLORINE-4-FLUORINE- PHENYLAMINE) -7 - (3 -MORFOLIN-4- IL -PROPOXI) - QUINAZOLIN- 6-IL] -ACRYLAMIDE, AN IRREVERSIBLE INHIBITOR OF THYROSINE KINASES
AP2002002694A0 (en) Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide dihydrochloride.
SI1131304T1 (en) N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl)-acrylamide, an irreversible inhibitor of tyrosine kinases
HK1029055A (en) Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
ECSP982362A (en) QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY